Development of Circulating Molecular Predictors of Chemotherapy and Novel Hormonal Therapy Benefit in Men With Metastatic Castration Resistant Prostate Cancer (mCRPC) (PCF)
Condition: Prostate CancerIntervention: Device: AR-v7 assaysSponsors: Duke University; Weill Medical College of Cornell University; Johns Hopkins University; Dana-Farber Cancer Institute; Memorial Sloan-Kettering Cancer Center; Epic Sciences; Prostate Cancer FoundationNot yet recruiting - verified October 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Chemotherapy | Hormonal Therapy | Hormones | Prostate Cancer | Research